Back to search results
NCT02315599

Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

Enrolling by Invitation
Not specifiedAges 1–99Observational
National Cancer Institute (NCI)
~500 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:anti-CD19 CAR

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Conduct long term safety evaluations after gene therapy
Measured over Every 3 months X 1 year then annually X 15 years

Conditions

Pediatric Cancers
Hematologic Malignancies
Solid Tumors

Explore related trials

Childhood Malignant NeoplasmHematologic NeoplasmSolid Neoplasm

NCT02315599

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • National Institutes of Health Clinical Center

    Bethesda, Marylandno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • John W Glod, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must be identified eligible for, participating in, or have participated in a POB genetically engineered cellular therapy clinical trial and have received/or be scheduled to receive a genetically engineered cellular therapy.
All monitoring and testing described in this protocol will pertain ONLY to genetically engineered cellular therapy received at the National Institutes of Health (NIH). RCR/RCL monitoring and persistence will NOT be followed for cells administered at another institution.

What this trial measures

  • Conduct long term safety evaluations after gene therapyEvery 3 months X 1 year then annually X 15 years

    PCR results (for RCR/RCL, gene transduced cells)